, Tracking Stock Market Picks
Enter Symbol:
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

down 6.87 %

Acorda Therapeutics, Inc. (ACOR) rated Buy with price target $50 by Aegis Capital

Posted on: Tuesday,  Oct 1, 2013  10:25 AM ET by Aegis Capital

Aegis Capital rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 10/01/2013. Previously Aegis Capital rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on
04/15/2013., when the stock price was $34.03. Since then, Acorda Therapeutics, Inc. has lost 6.88% as of 01/26/2016's recent price of $31.69.
If you would have followed the previous Aegis Capital's recommendation on ACOR, you would have lost 6.87% of your investment in 1016 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/1/2013 10:25 AM Buy
34.49 50.00
as of 12/13/2013
1 Week down  -5.73 %
1 Month down  -11.10 %
3 Months down  -16.91 %
1 YTD down  -13.68 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/15/2013 11:25 AM Buy
34.03 40.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy